We break down 12 randomized trials that layer lifestyle with targeted compounds to prevent or delay dementia. The data show where combinations help, where they fail, and why precision targeting and smarter trial designs matter for real-world brain health.
• Limits of antibody eligibility and why lifestyle leads
• Fourteen modifiable risk factors and the 45% prevention potential
• FINGER as the global template for multidomain change
• Who benefits: SCD, MCI, and prodromal AD populations
• Add-ons tested: omega-3s, vitamin D, Souvenaid, EGCG, metformin
• MAPT’s subgroup wins in amyloid-positive and high vascular risk groups
• SYNERGIC finding that vitamin D added no extra benefit
• Souvenaid plus lifestyle feasibility and adherence
• MET-FINGER’s precision prevention for APOE4 with metabolic risk
• PENSA’s delayed effects after washout and what it implies
• Heterogeneity problems and the need for factorial designs
• Biomarker breakthroughs enabling better recruitment and monitoring
• Toward layered, personalized, lifelong brain-health strategies
What is the one factor you could maybe focus on changing, even slightly, starting this week?
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.

Never miss an episode—subscribe on your favorite podcast app!